C2 Pharma, the global leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), announced the approval of a C-DMF for digoxin, an API manufactured by our Polish manufacturing partner Nobilus Ent. This milestone comes after a challenging three-year journey, due to global disruptions caused by the Covid pandemic.
The approval covers both digoxin and digoxin micronized. It supports different dosage forms i.e., oral and injectable drug product formulations. Digoxin is derived from the leaves of the Digitalis lanata plant and as a cardiac glycoside, it is commonly used in clinical practice for the treatment of mild to moderate heart failure.
